Publications

5808 Results

With > 4,600 patient-years follow-up, SWOG colorectal adjuvant study suggests that BCG may act as a chemoprevention agent.

Authors
F Panettiere
Journal / Conference
ASCO 13:171(#477)
Year
1994
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-7510

Patterns of failure and second malignancies from SWOG-8269: Concurrent cisplatin (P), etoposide (E), vincristine (V), and once daily radiotherapy (RT) for the treatment of limited small-cell lung cancer (SCLC).

Authors
L Janaki;D Rector;A Turrisi;J McCracken;R Livingston;S Giri;W Gordon;J Crowley
Journal / Conference
ASCO 13:331(#1096)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8269

Long term follow-up (F/U) from SWOG 8269: Concurrent cisplatin (P), etoposide (E), vincristine (V) and daily radiotherapy (TRT) for the treatment of limited small-cell lung cancer (LSCLC): Patterns of failure and second tumors.

Authors
A Turrisi;D Rector;LM Janaki;JD McCracken;R Livingston;SP Giri;W Gordon;J Crowley
Journal / Conference
Lung Cancer 11(Suppl.1):172(#666)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8269

African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.

Authors
S Dahlberg;RI Fisher;CA Coltman
Journal / Conference
ASCO 13:370(#1251)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8410, SWOG-8503, SWOG-8508, SWOG-8516 (INT-0067)

Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B.

Authors
ER Gaynor;S Dahlberg;RI Fisher
Journal / Conference
ASCO 13:370(#1250)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8516 (INT-0067)

Standard VAD (SWOG-8624) versus total therapy (TT) with 2 autotransplants (AT) for untreated multiple myeloma (MM).

Authors
J Crowley;S Jagannath;S Salmon;DH Vesole;G Tricot;B Barlogie
Journal / Conference
ASCO 13:410(#1401)
Year
1994
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624

Phase III randomized trial of infusional AZQ (diaziquone) versus IV BCNU for supratentorial malignant astrocytoma (MA): SWOG 8737.

Authors
KA Jaeckle;C Upchurch;SJ Green;HJ Eyre;H Knudsen;R Morantz;FS Vogel;JM Hamilton
Journal / Conference
ASCO 13:177(#496)
Year
1994
Research Committee(s)
Brain
Study Number(s)
SWOG-8737

Concurrent cisplatin/etoposide (PE) plus chest radiation followed by surgery for stages 3A(N2) and 3B non-small cell lung cancer: Completed analysis of SWOG-8805.

Authors
K Albain;V Rusch;J Crowley;A Turrisi;T Rice;R Livingston
Journal / Conference
ASCO 13:337(#1120)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8805

The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.

Authors
A Lichter;S Green;K Albain;L Hutchins;S Martino
Journal / Conference
ASCO 13:62(#51)
Year
1994
Research Committee(s)
Breast
Study Number(s)
SWOG-8814, SWOG-8897

Intraperitoneal (IP) mitoxantrone vs. intraperitoneal floxuridine in ovarian cancer patients with minimal residual disease after second-look surgery, a randomized phase II pilot.

Authors
F Muggia;D Alberts;P Liu;K Terada;D Wallace
Journal / Conference
ASCO 13:249(#782)
Year
1994
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8835